9 recruiting, 5 completed, 2 not yet recruiting, 1 active not recruiting. 20 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Recruiting 9, Completed 5, Not yet recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Blue Earth Diagnostics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer Posluma PET - Prostate Cancer | Phase 2 | Not yet recruiting | Aditya Bagrodia | 22 | 2026-08-01 | 2026-08-14 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [68Ga]BED003 - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-06-30 | 2026-09-15 |
| Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation Flotufolastat F18 PET - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | University of California, Irvine | 60 | 2026-05-01 | 2026-05-06 |
| Androgen-responsive POSLUMA-guided Intra-prostatic Boost PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost - Intermediate Risk Prostate Cancer, High Risk Prostate Cancer | Phase 2 | Recruiting | Martin T. King, MD, PhD | 23 | 2026-04-29 | 2026-05-29 |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [18F]FPyQCP - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-02-19 | 2026-10-28 |
| Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18 - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2026-02-10 | 2026-02-23 |
| An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography - Prostate Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 81 | 2025-10-09 | 2026-09-29 |
| PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence 18F-rhPSMA-7.3 (Posluma) - Prostate Cancer (Post Prostatectomy) | Phase 2 | Recruiting | AdventHealth | 30 | 2024-09-20 | 2024-10-24 |
| Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Active not recruiting | Emory University | 20 | 2023-04-27 | 2025-10-27 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis 18F-Fluciclovine - Brain Metastases, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 20 | 2023-01-10 | 2025-12-01 |
| Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma Fluciclovine PET guided Radiotherapy - Newly Diagnosed Glioblastoma | Phase 2 | Unknown | St. Joseph's Hospital and Medical Center, Phoenix | 100 | 2021-06-07 | 2023-01-13 |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Positron Emission Tomography, Lymphadenectomy, Radiation Therapy - Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 100 | 2020-09-30 | 2026-07-07 |
| Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) 18F fluciclovine - Brain Metastases | Phase 2 | Completed | Blue Earth Diagnostics | 23 | 2020-08-31 | 2025-07-20 |
| 18F-Fluciclovine PET and Multiparametric MR Imaging PET/CT with F-Fluciclovine (Axumin) - Brain Tumor, Recurrent, Adult | Phase 2 | Withdrawn | Loma Linda University | 2020-08-24 | 2024-09-03 | |
| 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies 18F-fluciclovine PET Scan - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Completed | Tulane University | 9 | 2020-01-30 | 2025-09-22 |
| [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors [18F]FLT, [18F]Fluciclovine - Brain Tumor | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2018-09-24 | 2024-12-27 |
| High Resolution PET-MRI Before Prostate Cancer HIFU 18F-Fluciclovine - Prostate Cancer | Phase 2 | Completed | Timothy J. Daskivich | 21 | 2017-12-07 | 2021-02-21 |
| FACBC Prostate Therapy Response FACBC PET-CT, MRI, CT, or Bone Scan - Prostate Cancer | Phase 2 | Completed | Emory University | 7 | 2016-07-01 | 2020-01-07 |
| Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI PET/CT, PET/MRI, mpMRI - Prostate Carcinoma | Phase 2 | Completed | Turku University Hospital | 26 | 2013-12-01 | 2016-10-21 |
Prostatic Neoplasms (11) · Brain Neoplasms (4) · Carcinoma, Lobular (2) · Carcinoma, Ovarian Epithelial (2) · Colorectal Neoplasms (2) · Stomach Neoplasms (2) · Disease (1) · Neoplasms (1) · Recurrence (1) · Urogenital Diseases (1)
fluciclovine F-18 (7) · Magnetic Resonance Spectroscopy (4) · X-Rays (2) · bicalutamide (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Furosemide (1) · Glutamate Carboxypeptidase II (1) · Leuprolide (1) · Lymph Node Excision (1) · Multiparametric Magnetic Resonance Imaging (1) · Positron Emission Tomography Computed Tomography (1) · Prednisone (1) · Radiation (1)
United States (17) · Finland (1) · Italy (1) · Netherlands (1)
Aditya Bagrodia, MD, FACS (1) · Ashutosh Tewari (1) · Brian Lewis, MD, MPH, FACP (1) · Charles V. Marcus, MBBS (1) · David Schuster, MD (1) · Eugene Teoh, MD (1) · Evan Yu (1) · Heikki Minn, Professor (1) · Jeffrey Yap, PhD (1) · Michael Daneshvar, MD (1) · Rohan Garje, M.D. (1) · Rupesh Kotecha, MD (1) · Rupesh R Kotecha, M.D. (1) · Steven Rowe, MD (1) · Timothy Daskivich, MD (1)
PMID 34081125, PMID 29147764, PMID 39848765
2025 (1), P30CA138292 (1)